Sullivan Ryan J, Atkins Michael B
Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Methods Mol Biol. 2014;1102:11-26. doi: 10.1007/978-1-62703-727-3_2.
The standard of care of patients with malignant melanoma is dramatically changing, hallmarked by the approval of three new agents for the treatment of malignant melanoma in 2011. In this changing therapeutic landscape, several clinical issues are emerging which will best be addressed through the application of advances in molecular analytics, diagnostics, and therapeutics. It is expected that dedicated and coordinated efforts in basic, translational, and clinical will be responsible for the next major breakthroughs in the care of patients with this dreaded disease. In this chapter, five critical, emerging clinical issues are presented with descriptions of approaches that might be expected to help solve these challenges to optimal patient care.
恶性黑色素瘤患者的护理标准正在发生巨大变化,其标志是2011年三种治疗恶性黑色素瘤的新药获批。在这不断变化的治疗格局中,出现了几个临床问题,通过应用分子分析、诊断和治疗方面的进展能最好地解决这些问题。预计基础、转化和临床方面的专门且协调的努力将促成这种可怕疾病患者护理方面的下一个重大突破。在本章中,介绍了五个关键的、新出现的临床问题,并描述了有望帮助解决这些挑战以实现最佳患者护理的方法。